Financial Contrast: Cibus (CBUS) vs. Its Peers

Cibus (NASDAQ:CBUS) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Cibus to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, profitability, earnings, risk and dividends.

Volatility & Risk

Cibus has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Cibus’ rivals have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cibus and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cibus	$3.64 million	-$127.08 million	-0.66
Cibus Competitors	$700.54 million	$9.44 million	-18.96

Cibus’ rivals have higher revenue and earnings than Cibus. Cibus is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Cibus and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Cibus Competitors	-12,323.33%	-195.91%	-30.60%

Insider and Institutional Ownership

33.8% of Cibus shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 29.9% of Cibus shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Cibus and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1	1	1	0	2.00
Cibus Competitors	9869	15284	45614	1598	2.54

Cibus presently has a consensus price target of $9.00, indicating a potential upside of 725.69%. As a group, “Biotechnology” companies have a potential upside of 125.37%. Given Cibus’ higher possible upside, equities research analysts plainly believe Cibus is more favorable than its rivals.

Summary

Cibus rivals beat Cibus on 7 of the 12 factors compared.

Cibus Company Profile

Cibus, Inc. (NASDAQ: CBUS) is an agricultural biotechnology company focused on developing gene-edited crop traits. Its technology is designed to improve the performance, resilience and sustainability of important crops by making targeted changes to plant genetics without introducing foreign DNA. The company’s proprietary Rapid Trait Development System (RTDS) supports the development of traits for crops including canola, rice, soybeans and wheat. Cibus has pursued applications such as herbicide tolerance, pod-shatter reduction and resistance to diseases and other environmental stresses, with the goal of helping growers improve yields, reduce crop losses and use agricultural inputs more efficiently.